Search
for
Sort by
Research 151–180 of 1000+
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Combination Therapy With CGF and Microneedling‐Assisted Compound Betamethasone for Resistant Alopecia Areata: APilot Study
- Successful Treatment of Alopecia Totalis with Topical Calcipotriol: Serial Case Report and Review of the Literature
- Tofacitinib for the treatment of alopecia areata and variants in adolescents
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Wharton’s jelly-derived mesenchymal stem cells in the treatment of four patients with alopecia areata
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years
- Alopesia universalis pada anak yang berespon baik dengan terapi kombinasi: sebuah laporan kasus
- Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- 40062 Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: a multicentric study
- Superficial Cryotherapy Versus Intralesional Corticosteroid Injection In Alopecia Areata: A Comparative Clinical And Dermoscopic Study
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics